AnaptysBio - Overview
About
Overview
Strategy
Senior Leadership
Board of Directors
Scientific Advisory Board
Contact
Science
Immune Cell Modulation
Listen to Short Takes on Deep Science
Anaptys Publications and Relevant Literature
Pipeline
Overview
Rosnilimab
ANB033
ANB101
Partnerships
Investors / News
Overview
News
Presentations & Events
Governance
Stock Information
Analyst Coverage
SEC Filings
Investor FAQs
Contact
Careers
Overview
See Where We Work
Total Rewards Program Highlights
Get to Know Our Team
Join Team Anaptys!
Contact
Toggle
Overview
Rosnilimab
Overview
Rheumatoid Arthritis
Ulcerative Colitis
ANB033
Overview
Celiac Disease
ANB101
Partnerships
Pipeline
Development Stage and Anticipated Milestones
Therapeutic
Indication
Antibody
Program
IND Enabling
Phase 1
Phase 2
Phase 3
Rosnilimab
(Pathogenic T cell depleter)
P2 data through
Week 12 anticipated
Nov./Dec. 2025
ANB033
(CD122 antagonist)
Celiac Disease
Ulcerative Colitis
Rheumatoid Arthritis
P1b to initiate
in 2026
Inflammatory Disease
P2b trial complete
ACR late-breaker
on Oct. 29th
Immune Cell Modulators
P1 in healthy
volunteers ongoing
ANB101
(BDCA2 modulator)
Inflammatory Disease